A New Insight into Hepatitis C Vaccine Development

Table 3

Main vaccines in clinical trials for HCV.

Vaccine	Subject	Stage	Outcome	Ref.
Peptides (core, NS3, NS4)/poly-L-arginine (IC41)	60 HLA-A2^+ chronic HCV nonresponders	II	67% responding to peptide plus adjuvant treatment versus 17% to peptide alone; 3 patients with transient decline of serum HCV RNA (>1 log)	[81]
Peptide (core)/ emulsified with ISA51	26 chronic HCV patients	I	Well tolerated with no severe toxicity; 15/25 responder; 2/25 with 1 log decline on HCV RNA	[82]
Peptides (NS3)/Virosome	30 healthy volunteers	I	No result released	NCT004; 45419
MVA-HCV NS3/NS4/NS5B (TG4040)	15 chronic HCV patients	I	Well tolerated; 6/15 with decline on HCV RNA (0.5–1.4 log)	[83]
HCV gpE1/E2 glycoproteins/MF59	60 healthy volunteers	I	No result released	NCT005; 00747
Recombinant yeast transfect with HCV NS3-core fusion protein (GI5005)	Chronic HCV patients	II	Well tolerate and showed better virology response in chronic patients after triple therapy	[84]
HCV core protein/ ISCOMATRIX	30 healthy volunteers	I	Well tolerated with mild local redness; all developed antibody response, 7/8 showed cytokine production & 2/8 showed cytotoxic T cell response in the group with highest antigen dose (50 𝜇g)	[85]
NS3/4A DNA vaccine (ChronVac-C)	12 chronic HCV patients	I/IIa	Safe, immunogenic with transient effect on serum viral load	[86]
Recombinant core protein & core/E1/E2 DNA vaccine (CIGB-230)	15 chronic HCV patients	I	Safe, immunogenic, and stabilized liver function with persistence detection of HCV RNA	[87]